Today marks the FDA's target deadline to act on a request that would give approximately 314,000 American children and adolescents with Type 1 diabetes a first-ever option: inhaled mealtime insulin that requires no needle. May 29, 2026 is the Prescription Drug User Fee Act target action date assigned to MannKind Corporation's supplemental biologics license application for Afrezza (insulin human) Inhalation Powder in patients aged 4 to 17. As of publication, the FDA had not announced a decision.
If approved, Afrezza would become the first needle-free mealtime insulin ever available to pediatric patients — a milestone that would arrive more than a century after insulin was first developed as an injectable treatment in 1921.
Injection anxiety is not a trivial clinical problem. Pediatric endocrinologists have documented for years that fear of needles drives skipped doses, inconsistent glycemic control, and long-term complications in young patients, particularly in school settings where self-administration is difficult or stigmatizing. An inhaled option, if it can be shown to work as well as injected insulin, changes the practical calculus for families managing daily diabetes care.
Afrezza Pediatric Approval: From Phase 3 Trial to Decision Day
The application rests on data from INHALE-1, a 26-week, open-label, randomized Phase 3 clinical trial that enrolled 230 children and adolescents between the ages of 4 and 17 with either Type 1 or Type 2 diabetes. Participants were randomized 1:1 to receive Afrezza combined with a basal insulin or multiple daily injections of a rapid-acting insulin analog also combined with basal insulin.
The FDA accepted MannKind's supplemental biologics license application in October 2025, assigning the May 29 PDUFA target action date. The company submitted the application on the basis of six-month INHALE-1 topline results reported in December 2024, supplemented by 52-week safety extension data. Full results were published in Diabetes Care in January 2026.
The primary endpoint was non-inferiority in HbA1c — a standard measure of average blood glucose control — at 26 weeks compared to multiple daily injections. Whether Afrezza cleared that bar depends on which population the FDA uses as its reference.
How Afrezza Works in the Lungs
Afrezza delivers insulin as an inhalable powder through a small, portable inhaler at the start of meals. The drug is built on MannKind's Technosphere platform, which uses microscopic fumaryl diketopiperazine (FDKP) crystals as carriers. When inhaled, insulin passes rapidly from lung tissue into the bloodstream — reaching peak concentrations within 10 to 15 minutes, faster than any injectable rapid-acting analog. The FDKP carrier dissolves and is excreted normally; the insulin itself begins lowering blood sugar in approximately 12 minutes and clears the system within one and a half to three hours, depending on dose.
For pediatric patients who struggle with daily injection routines, that speed and delivery route represent the therapy's core appeal. A child who inhales insulin at the start of a meal, rather than injecting before or after, faces a meaningfully different daily experience from current standard-of-care.
What the INHALE-1 Trial Data Shows
The FDA's benefit-risk assessment will center on a closely contested primary endpoint result and a set of secondary findings that favor Afrezza on patient experience.
In the full intent-to-treat (ITT) population, the mean difference in HbA1c change between the Afrezza group and the multiple daily injections group was 0.435 percentage points — just 0.035 points above the pre-specified non-inferiority margin of 0.4%. MannKind has attributed this result almost entirely to a single participant who did not adhere to the study protocol. When that participant was excluded in a modified ITT (mITT) analysis, the mean HbA1c difference dropped to 0.370%, establishing non-inferiority within the pre-specified threshold.
"Inhaled insulin is the fastest acting insulin available and is a valuable alternative to injected analogue insulin. Afrezza should be available as an option to all children and adults with type 1 diabetes," said Dr. Michael J. Haller, professor and chief of pediatric endocrinology at the University of Florida, who served as lead investigator for INHALE-1.
The secondary outcome picture adds weight to MannKind's case. Afrezza-treated children showed greater treatment satisfaction — measured across both patients and parents — and significantly less weight gain than those on multiple daily injections. Over 26 weeks, the injection group's body mass index increased by approximately 4% more than the Afrezza group. For a pediatric population in which insulin-associated weight gain is a documented clinical concern, that difference is meaningful.
Does Inhaled Insulin Affect Lung Function in Children?
Lung safety was closely tracked in INHALE-1 given Afrezza's known contraindication in adults with chronic lung disease such as asthma or COPD. Participants' lung function was monitored using forced expiratory volume in one second (FEV1) — a standard spirometry measure. In the Afrezza group, mean FEV1 was 99.6% of predicted at baseline and 96.6% at 26 weeks. In the multiple daily injections group, FEV1 was 102.3% of predicted at baseline and 98.0% at 26 weeks. The between-group difference was not statistically significant, and the trial found no serious lung-related complications. Both values remained within normal range throughout.
Hypoglycemia rates also showed no significant difference between the two groups over 26 weeks.
As a labeling matter, adults using Afrezza carry a warning about a potential lung cancer signal observed in earlier studies — too few cases to establish causation. Notably, on May 27, 2026 — two days before the PDUFA deadline — the FDA released MannKind from its long-standing postmarketing requirement to conduct a large, 8,000 to 10,000-patient study to assess pulmonary malignancy risk. The pediatric safety and efficacy assessment now stands as MannKind's sole remaining postmarketing obligation.
The Regulatory Calculus
The FDA has previously approved therapies on the basis of modified or sensitivity analyses — and the agency regularly weighs the totality of evidence when a primary endpoint result can be attributed to a specific, identifiable protocol deviation. Whether it will apply that same approach to the INHALE-1 ITT miss, given that the margin was exceeded by just 0.035 percentage points because of a single non-adherent participant, is the central regulatory question today.
The benefit side of the ledger includes a clean lung safety profile in pediatric patients, superior treatment satisfaction scores, and a weight gain advantage. The FDA must determine whether those secondary findings, combined with the mITT non-inferiority result, constitute a sufficient basis for approval for a population that currently has no needle-free mealtime insulin option at all.
Roy W. Beck, MD, PhD, founder of the Jaeb Center for Health Research and INHALE-1's oversight lead, has said of the study: "Having lived through one of my children developing type 1 diabetes, I know first-hand how overwhelming it is to find out that your child has been diagnosed with diabetes and has to start giving injections of insulin multiple times a day. The study will help evaluate whether replacing most of the injections with inhalations of insulin may lessen that burden for children and their families as they adjust to managing a lifelong disease."
What Comes Next for Pediatric Inhaled Insulin
MannKind's commercial pipeline extends beyond today's decision. The company is already running INHALE-1st, a separate Phase 3 trial that is enrolling up to 100 adolescents aged 10 to 17 with newly diagnosed Stage 3 Type 1 diabetes, evaluating Afrezza in combination with once-daily basal insulin from the outset of disease. The Barbara Davis Center in Aurora, Colorado is among approximately ten clinical sites enrolled in the study; data are expected in late 2027, per the company's SEC filings.
Whether today's FDA action is an approval, a complete response letter requesting additional data, or a label negotiation, MannKind plans to present nine new posters on Afrezza at the American Diabetes Association's 2026 Scientific Sessions in New Orleans, scheduled for June 5 to 8. The presentations will cover pediatric HbA1c and satisfaction data from INHALE-1, use with automated insulin delivery systems, and gestational diabetes applications.
For the approximately 314,000 children and adolescents in the United States living with diagnosed Type 1 diabetes, the regulatory question is whether the cumulative case — a near-miss primary endpoint, a clean lung safety record, and measurable quality-of-life advantages — is enough to bring the first inhaled insulin option in pediatric history across the finish line.
Frequently Asked Questions
Is inhaled insulin safe for children with diabetes?
INHALE-1 trial data showed no statistically significant difference in lung function between children using inhaled insulin and those on multiple daily injections over 26 weeks, and no serious lung-related complications were reported. Afrezza is contraindicated in patients with chronic lung disease such as asthma or COPD, and a spirometry lung function test is required before any prescription.
Can children use Afrezza instead of injections for diabetes?
As of May 29, 2026, Afrezza is approved for adults aged 18 and older in the United States. MannKind's application to expand the label to children and adolescents aged 4 to 17 reached its FDA decision deadline today; no regulatory action had been announced at time of publication. If approved, it would be the first needle-free mealtime insulin available to pediatric patients in more than a century of insulin therapy.
What is the FDA approval status of Afrezza for kids?
The FDA accepted MannKind's supplemental biologics license application for Afrezza in patients aged 4 to 17 in October 2025 and assigned a PDUFA target action date of May 29, 2026. As of publication, no approval or complete response letter had been announced.
How does Afrezza inhaled insulin work?
Afrezza uses MannKind's Technosphere delivery platform, which packages insulin in microscopic crystal carriers that dissolve when inhaled. Insulin passes from lung tissue into the bloodstream within one minute, reaches peak concentration in 10 to 15 minutes, and stops lowering blood glucose within one and a half to three hours — faster than any available injectable rapid-acting analog.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission.
